Swedish pharmaceutical company Moberg Pharma has completed enrolling patients in the ongoing Phase II trial of MOB-015 for the treatment of nail fungus (onychomycosis).

Sonepcizumab/LT1009-US-based Lpath has begun patient dosing in Phase 2a single-arm trial of anti-cancer drug, Asonep.

Mitsubishi Tanabe seeks manufacturing, marketing approval for TA-7284, Canagliflozin in Japan

New Drug Approvals

read all at

http://regulatoryaffairs.pharmaceutical-business-review.com/news/mitsubishi-tanabe-seeks-manufacturing-marketing-approval-for-ta-7284-in-japan-270513

CANAGLIFLOZIN

300px
CANAGLIFLOZIN
Canagliflozin
Canagliflozin is a highly potent and selective subtype 2 sodium-glucose transport protein (SGLT2) inhibitor to CHO- hSGLT2, CHO- rSGLT2 and CHO- mSGLT2 with IC50 of 4.4 nM, 3.7 nM and 2 nM, respectively.

M.F.C24H25FO5S
M.Wt: 444.52
CAS No: 842133-18-0
(1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol
1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
NMR…..http://file.selleckchem.com/downloads/nmr/S276003-Canagliflozin-HNMR-Selleck.pdf

Canagliflozin Hemihydrate
(1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hydrate (2:1)
928672-86-0

Canagliflozin (INN, trade name Invokana) is a drug of the gliflozin class, used for the treatment of type 2 diabetes.[1][2] It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson.[3]
U.S. Patent No, 7,943,788 B2 (the ‘788 patent) discloses canagliflozin or salts thereof and the process for its preparation.
U.S. Patent Nos. 7,943,582 B2 and 8,513,202 B2 discloses crystalline form of 1 -(P-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene hemihydrate and process for preparation thereof. The US ‘582 B2 and…

View original post 4,856 more words

Astellas Pharma and Medivation have announced the submission of application for marketing approval of enzalutamide in Japan for the treatment of prostate cancer

New Drug Approvals

enzalutamide

read all at

http://regulatoryaffairs.pharmaceutical-business-review.com/news/astellas-submits-marketing-application-of-enzalutamide-in-japan-270513

Enzalutamide, 20128.31FDA-approved treatment for advanced prostate cancer drugs. Enzalutamide the androgen receptor antagonist for the treatment of castration resistant prostate cancer (castration-ressitant prostate cancer). Enzalutamide Medivation developed by the trade name Xtandi.
Enzalutamide synthesis of amino acids by the compounds 1 and 2 obtained by the Ullmann coupling with methyl esterification of 3,3 isothiocyanate 4 (can be retrieved by the corresponding aniline and phosgene prepared sulfur) cyclization Enzalutamide

Prostate cancer is a threat to men’s health killer, according to incomplete statistics, their deaths after lung cancer. Metastatic prostate cancer refers to cancer cells by the prostate and surrounding tissue spread to other tissues or organs. Metastatic prostate cancer is usually divided into two phases: hormone sensitive period (the hormone-sensitive state) and castration tolerant phase (the castration-resistant state). Testosterone (testosterone) and other male hormones can provide nourishment prostate cancer cell growth.

View original post

New Route to Anticancer Agent Quinocarcin

New Drug Approvals

Compound Structure

Quinocarcin,

Antibiotic DC 52, DC 52, CHEBI:554143, CID158486, LS-80981, 3,6-Imino-1H-2-oxa-11c-azanaphth(1,2,3-cd)azulene-5-carboxylic acid, 2a,3,4,5,6,6a,7,11b-octahydro-11-methoxy-12-methyl-, (2a-alpha,3-alpha,5-alpha,6-alpha,6a-alpha,11b-alpha)-, (-)-, 84573-33-1

Synthesis of quinocarcin through a convergent strategy based on Sonogashira coupling and gold(I)-catalyzed hydroamination

Read more

View original post